Charles River Laboratories International Inc (CRL) FinancialsCRLCharles River Laboratories International Inc

Charles River Laboratories International, Inc. (CRL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DSA, accounting for 60.4% of total sales, equivalent to $606.51M. Other significant revenue streams include RMS and Manufacturing. Understanding this composition is critical for investors evaluating how CRL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Charles River Laboratories International, Inc. maintains a gross margin of 36.29%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.24%, while the net margin is -0.08%. These profitability ratios, combined with a Return on Equity (ROE) of -7.70%, provide a clear picture of how effectively CRL converts its operational activities into shareholder value.

In the context of the broader market, CRL competes directly with industry leaders such as ICLR and ULS. With a market capitalization of $13.92B, it holds a significant position in the sector. When comparing efficiency, CRL's gross margin of 36.29% stands against ICLR's 18.83% and ULS's 51.10%. Such benchmarking helps identify whether Charles River Laboratories International, Inc. is trading at a premium or discount relative to its financial performance.

Charles River Laboratories has shown strong revenue growth, with Q2 2026 revenue at $1 billion, surpassing market expectations. However, net income has been inconsistent, with losses reported in recent quarters, including a net loss of $14.8 million in Q1 2026.